Literature DB >> 2160197

A plasma inhibitor of platelet aggregation in patients with Argentine hemorrhagic fever.

D Cummins1, F C Molinas, G Lerer, J I Maiztegui, R Faint, S J Machin.   

Abstract

Hemorrhage in patients with Lassa fever is associated with the presence of a circulating plasma inhibitor of platelet aggregation. This study was to determine whether patients with Argentine hemorrhagic fever (AHF) develop a similar inhibitor. Normal platelets showed significantly weaker aggregation responses to a sub-maximal dose of adenosine diphosphate (ADP) when mixed with plasma from 10 patients with AHF (mean percent of control +/- 1 SE = 57.2 +/- 6.7%) compared to those mixed with plasma from 9 viral control patients (79.5 +/- 4.1%; P less than 0.05) and 9 febrile patients with septicemia (103.8 +/- 3%; P less than 0.001). Plasma from 3 patients with severe AHF inhibited in a dose-dependent fashion the aggregation responses of normal platelets to collagen, sodium arachidonate, a calcium ionophore (A23187), and ristocetin; none of 4 samples from convalescent AHF patients showed this inhibitory activity. The platelet inhibition was sudden in onset and unaffected by a 30 min pre-incubation, not neutralized by convalescent plasma with high titer antibody to Junin virus, and abolished after heating plasma from an AHF patient at 56 degrees C for 30 min. Hemorrhage in AHF is associated with the presence of a circulating inhibitor of platelet aggregation, and disturbed hemostasis in arenavirus-induced hemorrhagic fevers may have a common basis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2160197     DOI: 10.4269/ajtmh.1990.42.470

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  7 in total

1.  Junín virus infection of human hematopoietic progenitors impairs in vitro proplatelet formation and platelet release via a bystander effect involving type I IFN signaling.

Authors:  Roberto G Pozner; Agustín E Ure; Carolina Jaquenod de Giusti; Lina P D'Atri; Joseph E Italiano; Oscar Torres; Victor Romanowski; Mirta Schattner; Ricardo M Gómez
Journal:  PLoS Pathog       Date:  2010-04-15       Impact factor: 6.823

Review 2.  Platelets in Viral Infections - Brave Soldiers or Trojan Horses.

Authors:  Waltraud C Schrottmaier; Anna Schmuckenschlager; Anita Pirabe; Alice Assinger
Journal:  Front Immunol       Date:  2022-03-28       Impact factor: 7.561

Review 3.  The role of platelets in the pathogenesis of viral hemorrhagic fevers.

Authors:  Juan C Zapata; Dermot Cox; Maria S Salvato
Journal:  PLoS Negl Trop Dis       Date:  2014-06-12

4.  Metabolomics analyses identify platelet activating factors and heme breakdown products as Lassa fever biomarkers.

Authors:  Trevor V Gale; Timothy M Horton; Donald S Grant; Robert F Garry
Journal:  PLoS Negl Trop Dis       Date:  2017-09-18

5.  Rotational thromboelastometry alongside conventional coagulation testing in patients with Crimean-Congo haemorrhagic fever: an observational cohort study.

Authors:  Tom E Fletcher; Hakan Leblebicioglu; Ilkay Bozkurt; Mustafa Sunbul; Heval Bilek; Zahide Asik; Sener Barut; Ferdi Gunes; Umit Gemici; Roger Hewson; Duncan Wilson; Matt K O'Shea; Tom Woolley; Brian Faragher; Kiran Parmar; David G Lalloo; Nick J Beeching; Beverley J Hunt
Journal:  Lancet Infect Dis       Date:  2019-06-28       Impact factor: 71.421

6.  Endotheliopathy and Platelet Dysfunction as Hallmarks of Fatal Lassa Fever.

Authors:  Lucy E Horton; Robert W Cross; Jessica N Hartnett; Emily J Engel; Saori Sakabe; Augustine Goba; Mambu Momoh; John Demby Sandi; Thomas W Geisbert; Robert F Garry; John S Schieffelin; Donald S Grant; Brian M Sullivan
Journal:  Emerg Infect Dis       Date:  2020-11       Impact factor: 6.883

Review 7.  Pathogenic mechanisms involved in the hematological alterations of arenavirus-induced hemorrhagic fevers.

Authors:  Mirta Schattner; Leonardo Rivadeneyra; Roberto G Pozner; Ricardo M Gómez
Journal:  Viruses       Date:  2013-01-21       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.